The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.
Histopathology or cytology confirmed the lung squamous cell carcinoma
Age ranging from 18 to 75
Agree to participate in this study and sign an informed consent form
Treatment-naive tumor
Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form
Non-squamous NSCLC
Unresectable IIIa-IIIb tumor
Patients with solid organ or blood system transplantation
Second Xiangya Hospital of Central South University
Lead sponsor
Shanghai OrigiMed Co., Ltd.
Collaborator